Jane Hollingsworth

S1 BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drugs for the treatment of sexual dysfunction in both women and men. Its product portfolio include Lorexy's, Orexa, S1B-307, and S1B-3006. The company was founded in 2008 and is headquartered in New York, NY.

Militia Hill Ventures LLC creates and develops life sciences companies. The company is headquartered in Philadelphia, PA.

Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing novel therapies that enhance the body's ability to deliver oxygen. The firm's product candidate, Trans Sodium Crocetinate, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

Afimmune Ltd. operates as drug discovery and development company. It focuses on developing new medicines on inflammatory conditions of the human primary organs including the heart, the liver and the lung. The company was founded by John Climax and Ronan Lambe and is headquartered in Dublin, Ireland.

RiboNova, Inc. manufactures molecule drugs. The firm provides biomedical research services. The company was founded by David P. Hesson and is headquartered in Wynnewood, PA.

Spirovant Sciences, Inc. is a gene therapy company, which engages in the development of gene therapies for cystic fibrosis and other lung diseases. It offers AAV platform which consists of a highly optimized transgene payload, a novel AAV capsid, and an augmenter; and lentiviral platform, a pseudotyped with an envelope protein which has demonstrated capability to transduce human airway epithelia from apical surfaces. Its pipeline include SPIRO-2101, SPIRO-2102, and SPIRO 2110. The company was founded by Joan Lau and Eric Yuen and is headquartered in Philadelphia, PA.

Eliksa Therapeutics, Inc. is a biotechnology company that develops medicines for debilitating diseases using the regenerative properties of amniotic fluid and amniotic membrane. The company is based in Doylestown, PA. Eliksa Therapeutics was founded by Armen Karamanian, Jane Holmes Hollingsworth, and Armen Karamanian has been the CEO since incorporation.